Ligand based analysis on HMG-CoA reductase inhibitors

Chemometrics and Intelligent Laboratory Systems

Volumn 140, Issue , 2015, Pages 102-116

  Hari Narayana Moorthy, N S ^a   Cerqueira, Nuno M F S A ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cholesterol; Drug design; HMG CoA reductase inhibitors; Obesity; Pharmacophore; QSAR

Indexed keywords

EID: 84914166335     PISSN: 01697439     EISSN: 18733239     Source Type: Journal    
DOI: 10.1016/j.chemolab.2014.11.009     Document Type: Article

References (59)

1. Thilagavathi R., Kumar R., Aparna V., Sobhia M.E., Gopalakrishnan B., Chakraborti A.K. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA). Bioorg. Med. Chem. Lett. 2005, 15:1027-1032.
2. Kleemann R., Kooistra T. HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2005, 5:441-453.
3. Huff M.W., Telford D.E. Lord of the rings - the mechanism for oxidosqualene: lanosterol cyclase becomes crystal clear. Trends Pharmacol. Sci. 2005, 26:335-340.
4. Suzuki M., Iwasaki H., Fujikawa Y., Sakashita M., Kitaharac M., Sakodaa R. Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11:1285-1288.
5. Pfefferkorn J.A., Song Y., Sun K.L., Miller S.R., Trivedi B.K., Choi C., Sorenson R.J., Bratton L.D., Unangst P.C., Larsen S.D., Poel T.J., Cheng X.M., Lee C., Erasga N., Auerbach B., Askew V., Dillon L., Hanselman J.C., Lin Z., Lu G., Robertson A., Olsen K., Mertz T., Sekerke C., Pavlovsky A., Harris M.S., Bainbridge G., Caspers N., Chen H., Eberstadt M. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:4538-4544.
6. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999, 84:413-428.
7. Brown A.G., Smale T.C., King T.J., Hasenkamp R., Thompson R.H. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc. Perkin Trans. 1976, 11:1165-1170.
8. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:3957-3961.
9. Suzuki M., Iwasaki H., Fujikawa Y., Kitahara M., Sakashita M., Sakodaa R. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 2001, 9:2727-2743.
10. Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta 1986, 877:50-60.
11. Park W.K.C., Kennedy R.M., Larsen S.D., Miller S., Roth B.D., Song Y., Steinbaugh B.A., Sun K., Tait B.D., Kowala M.C., Trivedi B.K., Auerbach B., Askew V., Dillon L., Hanselman J.C., Lin Z., Lu G.H., Robertson A., Sekerke C. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:1151-1156.
12. Quirk J., Thornton M., Kirkpatrick P. Rosuvastatin calcium. Nat. Rev. Drug Discov. 2003, 2:769-770.
13. Larsen S.D., Poel T.J., Filipski K.J., Kohrt J.T., Pfefferkorn J.A., Sorenson R.J., Tait B.D., Askew V., Dillon L., Hanselman J.C., Lu G.H., Robertson A., Sekerke C., Kowala M.C., Auerbach B.J. Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design. Bioorg. Med. Chem. Lett. 2007, 17:5567-5572.
14. Pfefferkorn J.A., Litchfield J., Hutchings R., Cheng X.M., Larsen S.D., Auerbach B., Bush M.R., Lee C., Erasga N., Bowles D.M., Boyles D.C., Lu G., Sekerke C., Askew V., Hanselman J.C., Dillon L., Lin Z., Robertson A., Olsen K., Boustany C., Atkinson K., Goosen T.C., Sahasrabudhe V., Chupka J., Duignan D.B., Feng B., Scialis R., Kimoto E., Bi Y.A., Lai Y., El-Kattan A., Bakker-Arkema R., Barclay P., Kindt E., Le V., Mandema J.W., Milad M., Tait B.D., Kennedy R., Trivedi B.K., Kowala M. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution. Bioorg. Med. Chem. Lett. 2001, 21:2725-2731.
15. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev. Cardiovasc. Ther. 2007, 5:177-193.
16. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
17. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.
18. Wang X., Fang X., Xiao H., Yin Y., Xia H., Wua F. Synthesis of γ,γ-difluoro-β-hydroxy-δ-lactones as new precursors of HMG-CoA reductase inhibitor. J. Fluorine Chem. 2012, 133:178-183.
19. Duda-Seiman D.M., Avram S., Manca S., Careja V., Duda-Seiman C., Putz M.V., Ciubotariu D. MTD-CoMSIA modelling of HMG-CoA reductase inhibitors. J. Serb. Chem. Soc. 2011, 76:85-99.
20. Zhang Q.Y., Wan J., Xu X., Yang G.F., Ren Y.L., Liu J.J., Wang H., Guo Y. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening. J. Comb. Chem. 2007, 9:131-138.
21. Cercos-del-Pozo R.A., Perez-Gimenez F., Salabert-Salvador M.T., Garcia-March F.J. Discrimination and molecular design of new theoretical hypolipidemic agents using the molecular connectivity functions. J. Chem. Inf. Comput. Sci. 2000, 40:178-184.
22. Roth B.D., Ortwine D.F., Hoefle M.L., Stratton C.D., Sliskovic D.R., Wilson M.W., Newton R.S. Inhibitors of cholesterol biosynthesis. 1. Trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. J. Med. Chem. 1990, 33:21-31.
23. García I., Munteanu C.R., Fall Y., Gómez G., Uriarte E., González-Díaz H. QSAR and complex network study of the chiral HMGR inhibitor structural diversity. Bioorg. Med. Chem. 2009, 17:165-175.
24. García I., Fall Y., Gómez G. Review of synthesis, biological assay, and QSAR studies of HMGR inhibitors. Curr. Top. Med. Chem. 2012, 12:895-919.
25. García I., Fall Y., Gómez G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr. Drug Metab. 2010, 11:307-314.
26. Pfefferkorn J.A., Choi C., Song Y., Trivedi B.K., Larsen S.D., Askew V., Dillon L., Hanselman J.C., Lin Z., Lu G., Robertson A., Sekerke C., Auerbach B., Pavlovsky A., Harris M.S., Bainbridge G., Caspers N. Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:4531-4537.
27. Cai Z., Zhou W., Sun L. Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolemic agents. Bioorg. Med. Chem. 2007, 15:7809-7829.
28. Bratton L.D., Auerbach B., Choi C., Dillon L., Hanselman J.C., Larsen S.D., Lu G., Olsen L., Pfefferkorn J.A., Robertson A., Sekerke C., Trivedi B.K., Unangst P.C. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase. Bioorg. Med. Chem. 2007, 15:5576-5589.
29. Zhao S., Zhou W., Liu J. Synthesis and HMG-CoA reductase inhibition of 2-cyclopropyl-4-thiophenylquinoline mevalonolactones. Bioorg. Med. Chem. 2009, 17:7915-7923.
30. Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., Altman R.B., Klein T.E. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 2012, 92:414-417.
31. Grabowski E.J.J., Reider P.J., Tillyer R.D., Xu F. Crystalline Hydrated Dihydroxy Open-acid Simvastatin Calcium Salt. EP 1036783 A1 2000.
32. MOE 2012 2012, Chemical Computing Group Inc., Montreal, H3A 2R7, Canada.
33. Lin A. QuaSAR-descriptors 2002, Chemical Computing Group Inc., Montreal, H3A 2R7 Canada.
34. Statistica (8.0) 2010, StatSoft Inc., Tulsa, OK, USA.
35. Topliss J.G., Edwards R.P. Chance factors in studies of quantitative structure-activity relationships. J. Med. Chem. 1979, 22:1238-1244.
36. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chemom. Intell. Lab. Syst. 2011, 109:101-112.
37. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. hERG binding feature analysis of structurally diverse compounds by QSAR and fragmental analysis. RSC Adv. 2011, 1:1126-1136.
38. Kiralj R., Ferreira M.M.C. Basic validation procedures for regression models in QSAR and QSPR studies: theory and applications. J. Braz. Chem. Soc. 2009, 20:770-787.
39. Baumann K., Stiefl N. Validation tools for variable subset regression. J. Comput. Aided Mol. Des. 2004, 18:549-562.
40. Eriksson L., Jaworska J., Worth A.P., Cronin M.T.D., McDowell R.M. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environ. Health Perspect. 2003, 111:1361-1375.
41. Heberger K., Kollár-Hunek K. Sum of ranking differences for method discrimination and its validation: comparison of ranks with random numbers. J. Chemometr. 2011, 25:151-158.
42. Kollár-Hunek K., Héberger K. Method and model comparison by sum of ranking differences in cases of repeated observations (ties). Chemom. Intell. Lab. Syst. 2013, 127:139-146.
43. Tóth G., Bodai Z., Héberger K. Estimation of influential points in any data set from coefficient of determination and its leave-one-out cross-validated counterpart. Comput. Aided Mol. Des. 2013, 27:837-844.
44. Chirico N., Gramatica P. Real external predictivity of QSAR models: how to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J. Chem. Inf. Model. 2011, 51:2320-2335.
45. 2. J. Mol. Graph. Model. 2002, 20:269-276.
46. Roy P.P., Roy K. On some aspects of variable selected for partial least squares regression models. QSAR Comb. Sci. 2008, 27:302-313.
47. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blocker using newer tools. J. Enzyme Inhib. Med. Chem. 2014, 29(3):317-324.
48. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. Comparative structural analysis of α-glucosidase inhibitors against difference species: a computational study. Arch. Pharm. 2012, 345:265-274.
49. Neter J., Wasserman W., Kunter M.H. Applied Linear Statistical Models: Regression, Analysis of Variance, and Experimental Designs 1990, Irwin, Homewood (IL). third ed.
50. Durbin J., Watson G.S. Testing for serial correlation in least squares regression. I. Biometrika 1950, 37:409-428.
51. Durbin J., Watson G.S. Testing for serial correlation in least squares regression. II. Biometrika 1951, 38:159-178.
52. Cruciani C., Crivori P., Carrupt P.A., Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. (Theochem) 2000, 503:17-30.
53. Chohan K.K., Paine S.W., Mistry J., Barton P., Davis A.M. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J. Med. Chem. 2005, 48:5154-5161.
54. Moorthy N.S.H.N., Sousa S.F., Ramos M.J., Fernandes P.A. Classification study of solvation free energy of organic molecules with machine learning techniques. RSC Adv. 2014, 4:61624-61630.
55. Thai K.M., Ecker G.F. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg. Med. Chem. 2008, 16:4107-4119.
56. Fells J.I., Tsukahara R., Liu J., Tigyi G., Parrill A.L. 2D binary QSAR modeling of LPA3 receptor antagonism. J. Mol. Graph. Model. 2010, 28:828-833.
57. Powers D.M.W. Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation. J. Mach. Learn. Technol. 2011, 2:37-63.
58. Son M., Baek A., Sakkiah S., Park C., John S., Lee K.W. Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations. PLoS One 2013, 8:e83496.
59. Teli M.K., Rajanikant G.K. Pharmacophore generation and atom-based 3D-QSAR of N-iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors. Org. Med. Chem. Lett. 2012, 2:25.